Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM L JOHNSON

Allopathic & Osteopathic Physicians Pediatrics Pediatric Allergy/Immunology

NPI
1669476495
CMS profile
302077
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,663.83

103 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,663.83 103

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM L JOHNSON

NPI 1669476495 · CMS profile ID 302077

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Allergy/Immunology

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM L JOHNSON, NPI 1669476495, CMS profile ID 302077. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). WILLIAM L JOHNSON, NPI 1669476495, CMS profile ID 302077. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
WILLIAM L JOHNSON, NPI 1669476495, CMS profile ID 302077, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–103 of 103 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1669476495?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

103 matching records · $1,663.83 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 103 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–103 of 103.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $14.4301/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829568497 CMS
AstraZeneca Pharmaceuticals LP $40.1901/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829781569 CMS
Grifols USA, LLC $20.7801/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 846777369 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $542.26 34
PY2020 $767.13 43
PY2021 $1,663.83 103
PY2022 $2,374.87 138
PY2023 $1,164.21 57
PY2024 $175.00 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $741,690.33 83

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

83 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI US SERVICES INC. $2,500.00 12/22/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158198
Principal investigator 1 Genentech, Inc. $7,944.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625658
Principal investigator 1 Genentech, Inc. $156.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625661
Principal investigator 1 Genentech, Inc. $130.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625666
Principal investigator 1 Genentech, Inc. $624.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625671
Principal investigator 1 Genentech, Inc. $255.45 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625675
Principal investigator 1 Genentech, Inc. $269.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625678
Principal investigator 1 Genentech, Inc. $1,268.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625681
Principal investigator 1 Genentech, Inc. $1,031.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625685
Principal investigator 1 Genentech, Inc. $1,101.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625687
Principal investigator 1 Genentech, Inc. $2,639.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625693
Principal investigator 1 Genentech, Inc. $260.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625698
Principal investigator 1 Genentech, Inc. $130.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625703
Principal investigator 1 Genentech, Inc. $324.00 12/16/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211625707
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,070.27 12/11/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047572
Principal investigator 1 Genentech, Inc. $14,029.00 11/21/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625642
Principal investigator 1 Genentech, Inc. $19,532.00 11/21/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625645
Principal investigator 1 Genentech, Inc. $510.00 11/20/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625634
Principal investigator 1 Genentech, Inc. $2,639.00 11/20/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625638
Principal investigator 1 Genentech, Inc. $5,353.00 11/20/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625648
Principal investigator 1 Genentech, Inc. $312.00 11/20/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625654
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $7,896.17 11/20/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047570
Principal investigator 1 Verona Pharma, Inc. $8,181.21 11/19/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891557
Principal investigator 1 SANOFI US SERVICES INC. $3,489.00 11/17/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158195
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,605.00 10/24/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185549823
Principal investigator 1 SANOFI US SERVICES INC. $3,044.60 10/06/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158190
Principal investigator 1 Genentech, Inc. $234.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625598
Principal investigator 1 Genentech, Inc. $590.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625601
Principal investigator 1 Genentech, Inc. $404.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625606
Principal investigator 1 Genentech, Inc. $3,972.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625612
Principal investigator 1 Genentech, Inc. $354.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625615
Principal investigator 1 Genentech, Inc. $234.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625622
Principal investigator 1 Genentech, Inc. $413.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625624
Principal investigator 1 Genentech, Inc. $404.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625627
Principal investigator 1 Genentech, Inc. $312.00 10/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625631
Principal investigator 1 Genentech, Inc. $26,215.00 10/01/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625618
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $263.25 09/25/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047566
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $4,904.56 09/25/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047568
Principal investigator 1 SANOFI US SERVICES INC. $1,344.00 09/22/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158188
Principal investigator 1 Genentech, Inc. $11,986.00 09/09/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625596
Principal investigator 1 SANOFI US SERVICES INC. $15,615.40 09/08/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Moderatetosevere Asthma Who Participated in Study DRI16762 No dispute reported 06/30/2026 1226158176
Principal investigator 1 SANOFI US SERVICES INC. $5,989.00 09/08/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158184
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $450.00 08/21/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047564
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,443.89 08/19/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047562
Principal investigator 1 Verona Pharma, Inc. $9,500.00 08/15/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891501
Principal investigator 1 Verona Pharma, Inc. $1,750.00 08/15/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891503
Principal investigator 1 SANOFI US SERVICES INC. $3,896.00 08/11/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158172
Principal investigator 1 Genentech, Inc. $36,361.00 08/05/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625591
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,101.55 07/25/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047560
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,617.99 07/24/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047558
Principal investigator 1 SANOFI US SERVICES INC. $501.00 07/14/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158138
Principal investigator 1 SANOFI US SERVICES INC. $2,726.00 07/14/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158143
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,832.05 06/24/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047552
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $539.33 06/24/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047554
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,809.12 06/24/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047556
Principal investigator 1 SANOFI US SERVICES INC. $7,029.70 06/23/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158134
Principal investigator 1 SANOFI US SERVICES INC. $19,930.00 06/16/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158106
Principal investigator 1 SANOFI US SERVICES INC. $1,782.00 06/16/2025 Non-covered Recipient Entity
Midwest Clinical Research Center St Louis
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226158116
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,493.05 06/05/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047550
Principal investigator 1 Genentech, Inc. $3,125.00 06/03/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625530
Principal investigator 1 Genentech, Inc. $234.00 06/03/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625537
Principal investigator 1 Genentech, Inc. $130.00 06/03/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625582
Principal investigator 1 Genentech, Inc. $1,919.70 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625527
Principal investigator 1 Genentech, Inc. $454.98 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625540
Principal investigator 1 Genentech, Inc. $1,100.00 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625547
Principal investigator 1 Genentech, Inc. $234.00 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625550
Principal investigator 1 Genentech, Inc. $2,817.00 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625555
Principal investigator 1 Genentech, Inc. $234.00 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625561
Principal investigator 1 Genentech, Inc. $2,639.00 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625572
Principal investigator 1 Genentech, Inc. $241.17 05/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625588
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,699.45 04/24/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047548
Principal investigator 1 AstraZeneca UK Limited $31,293.98 04/14/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185549829
Principal investigator 1 Genentech, Inc. $3,263.10 04/10/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625564
Principal investigator 1 Genentech, Inc. $365.86 04/10/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625567
Principal investigator 1 Genentech, Inc. $156.00 04/10/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625577
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,051.80 04/09/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH
A Randomised Placebo-Controlled Double-Blind Multi-Centre 4-week 3-way Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide Glycopyrronium and Formoterol Fumarate (BGF) Delivered by MDI HFO Compared with BGF Delivered by MDI HFA in Participants with Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 1185549825
Principal investigator 1 AstraZeneca Pharmaceuticals LP $125,341.07 03/14/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH
A Phase II, Randomized, Double-blind, Single-dose, Placebo-controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study to Compare the Bronchodilatory Effect and Safety of PT007 AS MDI to Placebo MDI and Open-Label Ventolin Evohaler in Adult Participants with Asthma MITCHELL No dispute reported 06/30/2026 1185549827
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,834.72 02/27/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047546
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047578
Principal investigator 1 Genentech, Inc. $12,012.00 02/18/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211625518
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,617.99 01/30/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244047544
Principal investigator 1 Eli Lilly and Company $239,517.32 01/08/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LEBRIKIZUMAB/ LY3650150 IN ADULT PARTICIPANTS WITH PERENNIAL ALLERGIC RHINITIS No dispute reported 06/30/2026 1187885324
Principal investigator 1 Genentech, Inc. $12,914.00 01/02/2025 Non-covered Recipient Entity
MIDWEST CLINICAL RESEARCH LLC
Ph IIb of Astegolimab in COPD No dispute reported 06/30/2026 1211625522